AIDS Treatment Data Network
611 Broadway, Suite 613, New York, NY, 10012 • www.atdn.org • Tel: (212) 260-8868 • (NYS) 800-734-7104
The Access Project collects and distributes information about medications available for HIV/AIDS and hepatitis co-infection through Medicaid, Medicare Part D, AIDS Drug Assistance Programs (ADAPs), and pharmaceutical industry sponsored patient assistance and expanded access programs (EAP). The Access Project is a program of the The Network (network@atdn.org)

Bristol-Myers Squibb
AmeriCares Oncology/Virology Access Program

Products covered:

Blenoxane (bleomycin)
Hydrea (hydroxyurea)
Megace Oral Suspension (megestrol acetate)
Reyataz (atazanavir
Sustiva (efavirenz)
Taxol (paclitaxel)
VePesid (etoposide)
Videx, Videx EC (ddl, didanosine)
Zerit (stavudine, d4T) 1-800-272-4878




Contact
Program Eligibility
The patient must meet the following criteria to qualify:
  • Has no health insurance or no prescription coverage.
  • Not eligible for Medicaid, ADAP, or other drug assistance programs.
  • Income criteria is set lower than each state's AIDS Drug Assistance Program (ADAP).
Enrollment Process
The health care provider must call and provide the patient's income, insurance, and medical information. Bristol-Myers Squibb will then fax the application to the clinician's office after the initial enrollment call is made. A case management number will be assigned.
Re-Application
The health care provider must resubmit an application every 6-months.
Comments
Since enrollment is essentially handled over the phone, the turn around is done under 24-hours. The enrollee can expect their prescription to be available in 3-5 business days.

About The Network - Donate - About The Access Project
Last modified: 11/16/2007
© 2007 The Network